Drugs in Dev. Musculoskeletal
Phase IV
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The results from the completed PROTECT trial (NCT04087720) demonstrated that Krystexxa (Pegloticase & Methotrexate) provide a substantial and sustained decrease in serum uric acid (sUA) for patients with uncontrolled gout who had received a kidney transp...
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 04, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The findings indicated that the use of KRYSTEXXA with an immunomodulator may improve persistence to therapy. Approx 90% of the evaluated population met the sUA treatment target and those who received immunomodulation after starting on KRYSTEXXA were less...
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 01, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Results show that 71% (71 of 100) of patients who were randomized to receive KRYSTEXXA with methotrexate compared to 40% (21 of 52) of patients who were randomized to receive KRYSTEXXA with placebo achieved the primary endpoint (p<0.001).
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 25, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : University of Michigan
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Reducing Immunogenicity of Pegloticase trial showed that 86% of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL at 12 weeks vs 40% of patients (4 of 10) receiving KR...
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 07, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : University of Michigan
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The current recommended dosing of KRYSTEXXA for adult patients is 8 mg given as intravenous infusions every two weeks, with each dose infused over at least two hours.
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 25, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company announced two new KRYSTEXXA development programs: KRYSTEXXA, with methotrexate monthly dosing trial and a KRYSTEXXA retreatment trial evaluating KRYSTEXXA, with methotrexate, in patients who have previously failed KRYSTEXXA.
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 11, 2021
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The real-world usage analysis illustrates that KRYSTEXXA is effectively employed and well-tolerated among dialysis patients. KRYSTEXXA® is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to ...
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 22, 2020
Lead Product(s) : Pegloticase
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : In the open-label trial, 79 percent of patients who received both KRYSTEXXA and methotrexate (11 of 14 enrolled patients) maintained therapeutic response during Month 6 (defined as sUA <6 mg/dL).
Brand Name : Krystexxa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 16, 2020
Lead Product(s) : Pegloticase,Methotrexate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pegloticase
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Data presentations demonstrate that KRYSTEXXA® (pegloticase injection) can be co-prescribed with three commonly used immunomodulators in rheumatology to potentially help more people with chronic gout refractory to conventional therapies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
June 03, 2020
Lead Product(s) : Pegloticase
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : 80% of respondents experienced debilitating symptom recurrence, and revealed that a lack of long-lasting symptom control between injections has a profound impact on the personal and professional lives of patients.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 23, 2020
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
